FENC
Price
$10.32
Change
-$0.06 (-0.58%)
Updated
Oct 22 closing price
Capitalization
361.89M
21 days until earnings call
Intraday BUY SELL Signals
IPHA
Price
$1.51
Change
-$0.06 (-3.82%)
Updated
Oct 22 closing price
Capitalization
168.67M
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FENC vs IPHA

FENC vs IPHA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
FENC vs. IPHA commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FENC is a StrongBuy and IPHA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for FENC with price predictions
Oct 22, 2026

FENC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2026

FENC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 38 cases where FENC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 65 cases where FENC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for FENC just turned positive on October 20, 2026. Looking at past instances where FENC's MACD turned positive, the stock continued to rise in 37 of 48 cases over the following month. The odds of a continued upward trend are 77%.

Following a +4.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in 204 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FENC as a result. In 92 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The 10-day moving average for FENC crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FENC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for FENC entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.527) is normal, around the industry mean (2.973). FENC has a moderately low P/E Ratio (-86.000) as compared to the industry average of (-1.705). Projected Growth (PEG Ratio) (0.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.963) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FENC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for IPHA with price predictions
Oct 22, 2026

IPHA's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for IPHA moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 21 of the 24 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 78 cases where IPHA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on IPHA as a result. In 92 of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on October 20, 2026. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.

Following a +10.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in 148 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

IPHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

IPHA moved below its 50-day moving average on September 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IPHA crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for IPHA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.164) is normal, around the industry mean (2.973). P/E Ratio (-2.961) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (55.556) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IPHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
FENC vs IPHA: Fundamental Ratings
FENC
IPHA
OUTLOOK RATING
1..100
85
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
18
Undervalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
4262
P/E GROWTH RATING
1..100
4627
SEASONALITY SCORE
1..100
2150

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FENC's Valuation (3) in the Biotechnology industry is in the same range as IPHA (18) in the null industry. This means that FENC’s stock grew similarly to IPHA’s over the last 12 months.

FENC's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as IPHA (100) in the null industry. This means that FENC’s stock grew similarly to IPHA’s over the last 12 months.

FENC's SMR Rating (95) in the Biotechnology industry is in the same range as IPHA (98) in the null industry. This means that FENC’s stock grew similarly to IPHA’s over the last 12 months.

FENC's Price Growth Rating (42) in the Biotechnology industry is in the same range as IPHA (62) in the null industry. This means that FENC’s stock grew similarly to IPHA’s over the last 12 months.

IPHA's P/E Growth Rating (27) in the null industry is in the same range as FENC (46) in the Biotechnology industry. This means that IPHA’s stock grew similarly to FENC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FENCIPHA
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
79%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (FENC: $10.38 vs. IPHA: $1.57)
Brand notoriety: FENC and IPHA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FENC: 45% vs. IPHA: 39%
Market capitalization -- FENC: $361.89M vs. IPHA: $168.67M
FENC [@Biotechnology] is valued at $361.89M. IPHA’s [@Biotechnology] market capitalization is $168.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FENC’s FA Score shows that 1 FA rating(s) are green while IPHA’s FA Score has 2 green FA rating(s).

  • FENC’s FA Score: 1 green, 4 red.
  • IPHA’s FA Score: 2 green, 3 red.
According to our system of comparison, FENC is a better buy in the long-term than IPHA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FENC’s TA Score shows that 5 TA indicator(s) are bullish while IPHA’s TA Score has 6 bullish TA indicator(s).

  • FENC’s TA Score: 5 bullish, 3 bearish.
  • IPHA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both FENC and IPHA are a good buy in the short-term.

Price Growth

FENC (@Biotechnology) experienced а +4.01% price change this week, while IPHA (@Biotechnology) price change was +9.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

FENC is expected to report earnings on Nov 12, 2026.

IPHA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
FENC
Daily Signal:
Gain/Loss:
IPHA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

FENC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FENC has been loosely correlated with AMLX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if FENC jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FENC
1D Price
Change %
FENC100%
-0.58%
AMLX - FENC
37%
Loosely correlated
-1.58%
RZLT - FENC
37%
Loosely correlated
+4.32%
COYA - FENC
36%
Loosely correlated
N/A
REPL - FENC
35%
Loosely correlated
+2.30%
SEPN - FENC
34%
Loosely correlated
+0.29%
More

IPHA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IPHA has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IPHA jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHA
1D Price
Change %
IPHA100%
-3.82%
MDGL - IPHA
43%
Loosely correlated
-1.01%
ATYR - IPHA
37%
Loosely correlated
-1.33%
APLM - IPHA
36%
Loosely correlated
+4.75%
FENC - IPHA
34%
Loosely correlated
-0.58%
CCXI - IPHA
34%
Loosely correlated
-0.82%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TYA11.620.35
+3.11%
Simplify Intermediate Term Treasury Futures Strategy ETF (TYA)
DNP10.130.15
+1.50%
DNP Select Income Fund
KNRG25.270.13
+0.52%
Simplify Kayne Anderson Energy And Infrastructure Credit ETF
IGD6.38N/A
N/A
Voya Global Equity Dividend AND Premium Opportunity Fund
IOPP25.47N/A
N/A
Simplify Tara India Opportunities ETF (IOPP)